This review examines how neurotransmitters, neuropeptides (including CGRP), and stress hormones suppress anti-tumor immunity, and discusses therapeutic strategies including CGRP antagonism and beta-blockers to reactivate immune defenses against cancer.
Multiple neuromodulatory drug targets identifiedThe review proposes β-blockers, CGRP receptor antagonists, and NGF/BDNF inhibitors as combination partners for immune checkpoint inhibitors — several of which are already FDA-approved for other conditions.
What the researchers found
The review identifies multiple neuroimmune mechanisms in the tumor microenvironment: norepinephrine and cortisol modulate dendritic cell priming, NK cell cytotoxicity, CD8+ T-cell function, and myeloid polarization to create immunosuppression. Neuropeptides including CGRP contribute to immune evasion. Tumors drive their own neural innervation (tumor-associated neurogenesis), creating positive feedback loops. Therapeutic strategies discussed include β-adrenergic blockade, CGRP receptor antagonism, and inhibition of neurotrophic factors (NGF, BDNF). Combining immune checkpoint inhibitors with neuromodulation is proposed to overcome drug resistance.
Why it matters
Immune checkpoint inhibitors have revolutionized cancer treatment but work in less than half of patients. Understanding that the nervous system actively suppresses anti-tumor immunity reveals a major reason for treatment resistance — and opens new combination strategies. Several of the proposed interventions (beta-blockers, CGRP antagonists) already exist as approved drugs for other conditions, making clinical translation potentially rapid.
How the study worked
Critical review of published literature examining bidirectional neuroimmune interactions in the tumor immune microenvironment (TIME). Covers both how neural elements shape immune responses and how immune/tumor signals remodel neural circuits. Discusses preclinical and emerging clinical evidence for neuromodulatory cancer therapeutics.
What this study cannot tell us
Most evidence for neuroimmune interactions in cancer comes from preclinical models. The complexity of the tumor microenvironment means that targeting individual neural pathways may have limited impact. Clinical data for combining neuromodulation with immune checkpoint inhibitors is still emerging. The review covers many pathways broadly rather than providing deep mechanistic analysis of each. Species differences in neuroimmune signaling may limit translational relevance of animal studies.
How to read the evidence
This is a critical review synthesizing preclinical and early clinical evidence across the cancer neuroscience field. While comprehensive, the evidence for most proposed therapeutic combinations is still preclinical. The review identifies promising directions rather than proven therapies.
When this study was published
Published in 2025, this review captures the current state of the rapidly growing cancer neuroscience field, including the latest understanding of how neural signals shape tumor immunity.
The bigger picture
The field of cancer neuroscience is rapidly emerging as a new frontier. This review consolidates evidence that tumors don't just grow — they actively reshape their neural environment to suppress immunity. The intersection of neuropeptide biology and immuno-oncology is creating entirely new therapeutic paradigms. CGRP antagonists, already approved for migraine, are being reconsidered as cancer immunotherapy adjuncts — a remarkable example of peptide drug repurposing across completely different diseases.
Questions still open
- Which cancer types are most dependent on neuroimmune suppression and therefore most likely to respond to neuromodulatory combinations?
- Can CGRP antagonists (currently used for migraine) improve immunotherapy responses when added to cancer treatment regimens?
- Does chronic stress measurably accelerate cancer progression through the neuroimmune mechanisms described, and can beta-blockers prevent this?
Common questions
How do nerves help tumors escape the immune system?
Could migraine drugs or beta-blockers help fight cancer?
Read the original research
Dynamic interplay of neuroendocrine signaling and immuno-surveillance in tumor niche remodeling.
Critical reviews in oncology/hematology, 216, 104958
Citation
Xu, Nuo; Bian, Saiyan; Lyu, Pin; He, Xuyang; Zheng, Wenjie. (2025). Dynamic interplay of neuroendocrine signaling and immuno-surveillance in tumor niche remodeling.. Critical reviews in oncology/hematology, 216, 104958. https://doi.org/10.1016/j.critrevonc.2025.104958